A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
Speakers discussed common payer practices and policies that rheumatologists must navigate to secure and maintain appropriate care for their patients, including pharmacy benefit managers and prior authorization.
SAN DIEGO—At ACR Convergence 2023, panelists provided guidance for reducing disparities and improving health equity for patients who are negatively impacted by social determinants of health.
SAN DIEGO—The large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, experienced a surge of interest at ACR Convergence 2023. Here, we highlight important points from 10 of the studies presented at this conference.
Two ARP members who currently serve on the ACR Government Affairs Committee discuss why & how they got involved in advocacy.
Access to care is critical for treating arthritis and other chronic rheumatic conditions. That’s why choosing the best Medicare plan fit is such an important decision. Use these tips from the Arthritis Foundation’s Nick Turkas, MS, to help your patients make their best choice for insurance coverage.
The public health emergency (PHE), in place since 2020, officially expired at midnight on May 11. The PHE declaration allowed significant flexibility in the healthcare system. The end of the PHE impacts several policies, including changes in Medicare and Medicaid policies. What do these changes mean for providers?
Large language models are a type of AI that allows users to generate new content, drawing from a huge dataset to learn how to mimic “natural language” with many possible beneficial applications for this technology in medicine.
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
“What are you up to this weekend?” “Flying to Guam.” “What? Why?” “I promised an entire island I’d be their doctor.” In fall 2021, Jonathon Thorp, MD, phoned a friend. A passionate internist, he was bound and determined to bring a rheumatologist to Guam. Unlike most primary care providers (PCPs), he was willing to prescribe…